Sonoma Biotherapeutics is a biotech company focused on the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/04/2021 | Series B | $147.22MM | $xx.xx | $73.24B | 8vc, Alexandria Venture Investments, Ally Bridge Group, Arch Venture Partners, Arrowmark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, Gv, Janus Henderson Investors, Jdrf T1d Fund, Lifeforce Capital, Lilly Asia Ventures Biosciences, Mirae Asset, Ns Investment, Octagon Capital, Osage University Partners, Piper Heartland Healthcare Capital, Regeneron, Vertex Ventures Hc | |
Price per Share
$xx.xx
Shares Outstanding
74,494,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexandria Venture Investments, Ally Bridge Group, Arch Venture Partners, Arrowmark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, Gv, Janus Henderson Investors, Jdrf T1d Fund, Lifeforce Capital, Lilly Asia Ventures Biosciences, Mirae Asset, Ns Investment, Octagon Capital, Osage University Partners, Piper Heartland Healthcare Capital, Regeneron, Vertex Ventures Hc
|
||||||
08/04/2021 | Series B-1 | $147.78MM | $xx.xx | $73.24B | 8vc, Alexandria Venture Investments, Ally Bridge Group, Arch Venture Partners, Arrowmark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, Gv, Janus Henderson Investors, Jdrf T1d Fund, Lifeforce Capital, Lilly Asia Ventures Biosciences, Mirae Asset, Ns Investment, Octagon Capital, Osage University Partners, Piper Heartland Healthcare Capital, Regeneron, Vertex Ventures Hc | |
Price per Share
$xx.xx
Shares Outstanding
49,849,130
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexandria Venture Investments, Ally Bridge Group, Arch Venture Partners, Arrowmark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, Gv, Janus Henderson Investors, Jdrf T1d Fund, Lifeforce Capital, Lilly Asia Ventures Biosciences, Mirae Asset, Ns Investment, Octagon Capital, Osage University Partners, Piper Heartland Healthcare Capital, Regeneron, Vertex Ventures Hc
|
||||||
09/30/2020 | Series A | $70.1MM | $xx.xx | $11.68B | 8vc, Alexandria Venture Investments, Arch Venture Partners, Jdrf T1d Fund, Lifeforce Capital, Lilly Asia Ventures Biosciences, Lyell Immunopharma, Octagon Capital | |
Price per Share
$xx.xx
Shares Outstanding
70,100,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexandria Venture Investments, Arch Venture Partners, Jdrf T1d Fund, Lifeforce Capital, Lilly Asia Ventures Biosciences, Lyell Immunopharma, Octagon Capital
|